![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: IFI44L |
Gene summary for IFI44L |
![]() |
Gene information | Species | Human | Gene symbol | IFI44L | Gene ID | 10964 |
Gene name | interferon induced protein 44 like | |
Gene Alias | C1orf29 | |
Cytomap | 1p31.1 | |
Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | Q53G44 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10964 | IFI44L | CA_HPV_1 | Human | Cervix | CC | 8.07e-34 | 9.30e-01 | 0.0264 |
10964 | IFI44L | CA_HPV_2 | Human | Cervix | CC | 3.05e-19 | 5.30e-01 | 0.0391 |
10964 | IFI44L | CCI_2 | Human | Cervix | CC | 8.49e-04 | 4.65e-01 | 0.5249 |
10964 | IFI44L | CCI_3 | Human | Cervix | CC | 2.65e-02 | 4.06e-01 | 0.516 |
10964 | IFI44L | Tumor | Human | Cervix | CC | 2.97e-30 | 5.61e-01 | 0.1241 |
10964 | IFI44L | sample3 | Human | Cervix | CC | 4.71e-39 | 7.18e-01 | 0.1387 |
10964 | IFI44L | H2 | Human | Cervix | HSIL_HPV | 1.52e-05 | 2.85e-01 | 0.0632 |
10964 | IFI44L | T3 | Human | Cervix | CC | 1.22e-43 | 7.07e-01 | 0.1389 |
10964 | IFI44L | LZE5T | Human | Esophagus | ESCC | 1.05e-04 | 5.21e-01 | 0.0514 |
10964 | IFI44L | LZE8T | Human | Esophagus | ESCC | 5.65e-03 | 1.61e-01 | 0.067 |
10964 | IFI44L | LZE20T | Human | Esophagus | ESCC | 5.40e-12 | 5.67e-01 | 0.0662 |
10964 | IFI44L | LZE24T | Human | Esophagus | ESCC | 5.89e-30 | 9.82e-01 | 0.0596 |
10964 | IFI44L | P1T-E | Human | Esophagus | ESCC | 7.34e-06 | 8.08e-01 | 0.0875 |
10964 | IFI44L | P2T-E | Human | Esophagus | ESCC | 6.15e-58 | 1.26e+00 | 0.1177 |
10964 | IFI44L | P5T-E | Human | Esophagus | ESCC | 2.36e-13 | 3.69e-01 | 0.1327 |
10964 | IFI44L | P8T-E | Human | Esophagus | ESCC | 7.10e-26 | 6.57e-01 | 0.0889 |
10964 | IFI44L | P9T-E | Human | Esophagus | ESCC | 5.53e-34 | 9.52e-01 | 0.1131 |
10964 | IFI44L | P11T-E | Human | Esophagus | ESCC | 4.57e-20 | 1.01e+00 | 0.1426 |
10964 | IFI44L | P15T-E | Human | Esophagus | ESCC | 1.23e-12 | 5.13e-01 | 0.1149 |
10964 | IFI44L | P17T-E | Human | Esophagus | ESCC | 3.27e-16 | 1.04e+00 | 0.1278 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00096158 | Cervix | CC | response to virus | 73/2311 | 367/18723 | 2.22e-05 | 3.95e-04 | 73 |
GO:00516072 | Cervix | CC | defense response to virus | 46/2311 | 265/18723 | 1.04e-02 | 4.97e-02 | 46 |
GO:01405462 | Cervix | CC | defense response to symbiont | 46/2311 | 265/18723 | 1.04e-02 | 4.97e-02 | 46 |
GO:000961518 | Esophagus | ESCC | response to virus | 238/8552 | 367/18723 | 6.65e-14 | 3.32e-12 | 238 |
GO:00516075 | Esophagus | ESCC | defense response to virus | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
GO:01405465 | Esophagus | ESCC | defense response to symbiont | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
GO:00096155 | Liver | Cirrhotic | response to virus | 126/4634 | 367/18723 | 2.10e-05 | 2.77e-04 | 126 |
GO:0051607 | Liver | Cirrhotic | defense response to virus | 84/4634 | 265/18723 | 6.02e-03 | 3.00e-02 | 84 |
GO:0140546 | Liver | Cirrhotic | defense response to symbiont | 84/4634 | 265/18723 | 6.02e-03 | 3.00e-02 | 84 |
GO:000961511 | Liver | HCC | response to virus | 210/7958 | 367/18723 | 7.32e-09 | 1.86e-07 | 210 |
GO:00516071 | Liver | HCC | defense response to virus | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
GO:01405461 | Liver | HCC | defense response to symbiont | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
GO:000961515 | Oral cavity | OSCC | response to virus | 215/7305 | 367/18723 | 1.63e-14 | 9.41e-13 | 215 |
GO:00516074 | Oral cavity | OSCC | defense response to virus | 154/7305 | 265/18723 | 1.96e-10 | 5.63e-09 | 154 |
GO:01405464 | Oral cavity | OSCC | defense response to symbiont | 154/7305 | 265/18723 | 1.96e-10 | 5.63e-09 | 154 |
GO:000961516 | Oral cavity | LP | response to virus | 143/4623 | 367/18723 | 7.42e-10 | 3.52e-08 | 143 |
GO:005160711 | Oral cavity | LP | defense response to virus | 97/4623 | 265/18723 | 9.31e-06 | 1.74e-04 | 97 |
GO:014054611 | Oral cavity | LP | defense response to symbiont | 97/4623 | 265/18723 | 9.31e-06 | 1.74e-04 | 97 |
GO:000961521 | Oral cavity | EOLP | response to virus | 81/2218 | 367/18723 | 1.71e-08 | 7.66e-07 | 81 |
GO:005160721 | Oral cavity | EOLP | defense response to virus | 55/2218 | 265/18723 | 2.16e-05 | 3.35e-04 | 55 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IFI44L | SNV | Missense_Mutation | novel | c.1315N>C | p.Glu439Gln | p.E439Q | Q53G44 | protein_coding | deleterious(0.05) | possibly_damaging(0.856) | TCGA-05-4427-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
IFI44L | SNV | Missense_Mutation | c.307N>G | p.Thr103Ala | p.T103A | Q53G44 | protein_coding | tolerated(0.54) | benign(0.006) | TCGA-44-A4SS-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
IFI44L | SNV | Missense_Mutation | c.818N>C | p.Gly273Ala | p.G273A | Q53G44 | protein_coding | deleterious(0) | benign(0.439) | TCGA-49-AAR9-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
IFI44L | SNV | Missense_Mutation | c.479N>T | p.Gly160Val | p.G160V | Q53G44 | protein_coding | deleterious(0) | probably_damaging(0.958) | TCGA-55-7903-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
IFI44L | SNV | Missense_Mutation | novel | c.1235N>A | p.Pro412His | p.P412H | Q53G44 | protein_coding | deleterious(0.02) | benign(0.027) | TCGA-55-8506-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
IFI44L | SNV | Missense_Mutation | c.1340N>G | p.Ala447Gly | p.A447G | Q53G44 | protein_coding | tolerated(0.46) | benign(0) | TCGA-78-7155-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | PD | |
IFI44L | SNV | Missense_Mutation | c.1225G>C | p.Glu409Gln | p.E409Q | Q53G44 | protein_coding | deleterious(0.04) | probably_damaging(0.972) | TCGA-86-8279-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | etoposide | CR | |
IFI44L | SNV | Missense_Mutation | c.72N>T | p.Leu24Phe | p.L24F | Q53G44 | protein_coding | tolerated(0.56) | benign(0.372) | TCGA-86-8674-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | vinblastine | PD | |
IFI44L | SNV | Missense_Mutation | c.509N>T | p.Arg170Met | p.R170M | Q53G44 | protein_coding | deleterious(0) | possibly_damaging(0.694) | TCGA-L9-A5IP-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
IFI44L | SNV | Missense_Mutation | c.1180N>T | p.Pro394Ser | p.P394S | Q53G44 | protein_coding | tolerated(0.08) | possibly_damaging(0.871) | TCGA-18-3409-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |